论文部分内容阅读
目的观察重组人脑利钠肽(rhBNP)治疗人工心脏瓣膜置换术后心力衰竭的疗效及安全性。方法选取医院择期行人工心脏瓣膜置换术后心力衰竭的患者38例,给予rhBNP 0.0075~0.015μg/(kg·min),用微量泵持续静脉泵入72 h,监测血流动力学参数、血清生化指标及心脏超声。结果应用rhBNP后肺毛细血管楔压(PCWP)、N末端B型利钠肽明显下降(P<0.05),心率、平均动脉压、中心静脉压维持正常范围内,肝肾功能无明显变化。结论 rhBNP可改善人工瓣膜置换术后心力衰竭患者血流动力学障碍,安全有效。
Objective To observe the efficacy and safety of recombinant human brain natriuretic peptide (rhBNP) in the treatment of heart failure after artificial heart valve replacement. Methods Thirty-eight patients with HF after elective heart valve replacement were enrolled in this study. The patients were given rhBNP 0.0075 ~ 0.015μg / (kg · min), and the patients were treated by continuous intravenous infusion of micro-pump for 72 hours. The hemodynamic parameters, serum biochemistry Indicators and echocardiography. Results After administration of rhBNP, pulmonary capillary wedge pressure (PCWP) and N-terminal B-type natriuretic peptide were significantly decreased (P <0.05). Heart rate, mean arterial pressure and central venous pressure were within normal range. Conclusion rhBNP can improve the hemodynamics in patients with heart failure after prosthetic valve replacement and is safe and effective.